$LBPS News
Last published 4y ago
- 4y agoLBPS4D pharma plc ("4D pharma") Receives Notice of Delisting From NasdaqBusiness Wire4D pharma plc ((AIM: DDDD, NASDAQ:LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces that on June 27, 2022, it received written notice from T
- 4y agoLBPSUpdate on Suspension of TradingBusiness Wire4D pharma plc ((AIM: DDDD, NASDAQ:LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, provides an update to the announcement released earlier today regarding
- 4y agoLBPS4D pharma Presents Trial in Progress Poster on Study of MRx0518 in Combination with BAVENCIO® in Patients with Unresectable Locally Advanced or Metastatic Urothelial Carcinoma at the 2022 American Society of Clinical Oncology (ASCO) Annual MeetingBusiness Wire- Study to assess safety of MRx0518 with BAVENCIO and effect on progression-free survival at 6 months- Study sites are open for patient enrolment 4D pharma plc ((AIM: DDDD, NASDAQ:LBPS), a pharmaceutical company leading the development of Live Bioth
- 4y agoLBPS4D pharma to Present at the H.C. Wainwright Global Investment ConferenceBusiness Wire4D pharma plc ((AIM: DDDD, NASDAQ:LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announced that Duncan Peyton, Chief Executive Officer of 4D pharma
- 4y agoLBPS4D pharma Presents Late Breaking Abstract from Phase I/II Trial of MRx-4DP0004 for the Treatment of Asthma at the American Thoracic Society (ATS) 2022 International ConferenceBusiness Wire4D pharma plc ((AIM: DDDD, NASDAQ:LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces the presentation of a late-breaking poster on data from
- 4y agoLBPS4D pharma Reports Full Year 2021 Financial Results, Operational Highlights, and Guidance for Key Milestones in 2022Business Wire4D pharma plc ((AIM: DDDD, NASDAQ:LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today reported financial results for the full year ending December 31, 2
- 4y agoDNAHYMCLBPSNEXI+1Thinking about buying stock in Hycroft Mining, Nielsen, Neximmune, 4D pharma, or Ginkgo Bioworks?PR NewswireNEW YORK, March 29, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for HYMC, NLSN, NEXI, LBPS, and DNA.
- 4y agoCELZLBPSONCYREVB+1Optimism Builds for Promising Developments & New Drug Therapies Targeting Treatments for Breast CancerPR NewswirePALM BEACH, Fla., March 24, 2022 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - The status of breast cancer as one of the most commonly occurring cancers in the world is expected to be a key driving factor for the global market. As more and mor
- 4y agoCREXHYMCLBPSRZLT+1Thinking about buying stock in Hycroft Mining, Tilray, 4D pharma, Rezolute, or Creative Realities?PR NewswireNEW YORK, March 23, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for HYMC, TLRY, LBPS, RZLT, and CREX.
- 4y agoLBPS4D pharma Announces Positive Interim Results from the Phase I/II Study of the Combination of MRx0518 and KEYTRUDA® (pembrolizumab) for the Treatment of Renal Cell CarcinomaBusiness Wire- Primary Efficacy Endpoint Met Early in Renal Cell Carcinoma Group in Part B of Study - Company to Host Conference Call and Webcast Today March 23, 10:00 am EST (2:00 pm GMT) 4D pharma plc ((AIM: DDDD, NASDAQ:LBPS), a pharmaceutical company leadi
- 4y agoLBPS4D pharma to Participate at the Chardan Metagenomics and Microbiome Medicines SummitBusiness Wire4D pharma plc ((AIM: DDDD, NASDAQ:LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announced that Duncan Peyton, Chief Executive Officer, and Alex St
- 4y agoLBPS4D pharma Announces FDA Clearance of IND Application for Live Biotherapeutics MRx0005 and MRx0029 for the Treatment of Parkinson's DiseaseBusiness Wire- IND clearance marks the expansion of 4D pharma's clinical-stage pipeline of single strain Live Biotherapeutics into neurology - First US FDA IND clearance for a Live Biotherapeutic for Parkinson's disease 4D pharma plc ((AIM: DDDD, NASDAQ:LBPS),
- 4y agoLBPS4D pharma Announces Additional Positive Data From Part A of the Phase I/II Trial Of MRx-4DP0004 For the Treatment of AsthmaBusiness Wire- Part A of the trial achieved the primary endpoint of safety and tolerability - Multiple secondary endpoints show positive trends in improving asthma control, supporting progression into Part B of the Phase I/II trial - Company to host conference
- 4y agoLBPS4D pharma to Host Virtual KOL Event Discussing Asthma Treatment Landscape and Review of Positive Topline Results from Part A of Phase I/II Trial of MRx-4DP0004Business Wire4D pharma plc ((AIM: DDDD, NASDAQ:LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announced that it will host a virtual Key Opinion Leader (KOL) eve
- 4y agoLBPS4D pharma to Present at the H.C. Wainwright BioConnect ConferenceBusiness Wire4D pharma plc ((AIM: DDDD, NASDAQ:LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announced that Duncan Peyton, Chief Executive Officer of 4D pharma
- 4y agoLBPS4D pharma appoints John Doyle as Chief Financial OfficerBusiness Wire4D pharma plc ((AIM: DDDD, NASDAQ:LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces the appointment of John Doyle as Chief Financial Officer
- 4y agoLBPS4D Pharma Announces Positive Topline Results From Part a of Phase I/II Trial of MRx-4DP0004 for the Treatment of AsthmaBusiness WirePart A of the study meets primary endpoint of safety and tolerability Achieved multiple key secondary endpoints relating to improved asthma control compared to placebo 4D pharma plc ((AIM: DDDD, NASDAQ:LBPS), a pharmaceutical company leading the d
- 4y agoLBPS4D pharma Presents Microbiome Analyses from Phase II Clinical Trial of Blautix® for IBS-C and IBS-D at Gastro 2021Business WireResults demonstrate changes in gut microbiome structure following administration of Blautix in both IBS-C and IBS-D patients 4D pharma plc ((AIM: DDDD, NASDAQ:LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LB
- 4y agoDMTTFETONISCOLBPSSmall Pharma Strengthens Board With Appointment of Paul Maier as Independent DirectorGlobeNewswireLONDON, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV:DMT) (OTCQB:DMTTF) (the "Company" or "Small Pharma"), a neuropharmaceutical company focused on psychedelic-assisted therapies, announces that Mr. Paul Maier has been appointed as a non-e
- 4y agoINMBLBPSCoImmune, Inc. Appoints Ed Baracchini, PhD, Chairman of the Board of DirectorsGlobeNewswireDURHAM, N.C., Nov. 15, 2021 (GLOBE NEWSWIRE) -- CoImmune, Inc., a clinical stage immuno-oncology company working to redefine cancer treatment using best-in-class cellular immunotherapies, today announced the appointment of Dr. Ed Baracchini as chairman
- 5y agoLBPS4D pharma to Participate in Jefferies London Healthcare ConferenceBusiness Wire4D pharma plc ((AIM: DDDD, NASDAQ:LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces that 4D pharma management will participate in the Jeffer
- 5y agoLBPS4D pharma to Participate in Jefferies Virtual Next Generation IBD Therapeutics SummitBusiness Wire4D pharma plc (AIM: DDDD, NASDAQ, LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces that 4D management will present at the Jefferies Virtual
- 5y agoLBPS4D pharma Presents Two Clinical Posters for Live Biotherapeutic MRx0518 at the European Society for Medical Oncology (ESMO) Congress 2021Business Wire- One presentation details baseline biomarkers associated with clinical benefit from MRx0518, indicating a potential tumor biomarker predictive of response - The second presentation describes gene and metagene signature changes with MRx0518 monothe
- 5y agoLBPS4D pharma to Participate in Upcoming Virtual Investor Conferences in SeptemberBusiness Wire4D pharma plc ((AIM: DDDD, NASDAQ:LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces that 4D pharma management will present at the following
- 5y agoLBPS4D pharma Announces Two Presentations at European Society for Medical Oncology (ESMO) Congress 2021Business Wire4D pharma plc ((AIM: DDDD, NASDAQ:LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces two poster presentations at the European Society for Med
- 5y agoLBPS4D pharma Announces $30 Million Credit Facility with Oxford FinanceBusiness Wire4D pharma plc ((AIM: DDDD, NASDAQ:LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces the closing of a senior secured credit facility for up t
- 5y agoLBPS4D pharma Announces Passing of Chief Financial Officer John BeckBusiness Wire4D pharma plc (AIM: DDDD, NASDAQ, LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, announces with great sadness that John Beck, Chief Financial Officer of
- 5y agoLBPS4D pharma Announces Publication of Preclinical Research Showing Single Strain Megasphaera massiliensis improves activity of CAR-TBusiness Wire4D pharma plc ((AIM: DDDD, NASDAQ:LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces the publication of pre-clinical research relating to its
- 5y agoLBPS4D pharma to Present at the Microbiome Movement Drug Development SummitBusiness Wire4D pharma plc ((AIM: DDDD, NASDAQ:LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announces Christophe Carite, Development Director, will deliver a
- 5y agoLBPS4D pharma Completes Enrollment of Part A of the Phase I/II Trial of MRx-4DP0004 for the Treatment of Asthma and Provides Program UpdateBusiness Wire- Topline data from Part A of asthma study expected in 2H 2021 - Discontinuation of enrollment in Phase II study of MRx-4DP0004 for the treatment of hospitalized patient with COVID-19 4D pharma plc ((AIM: DDDD, NASDAQ:LBPS), a pharmaceutical compa
- 5y agoLBPS4D pharma Presents Additional Positive Results of Phase II Study of Blautix® for the Treatment of Irritable Bowel SyndromeBusiness WireNew data demonstrating clinical activity in both IBS-C and IBS-D was presented at Digestive Disease Week 2021 Company to host webcast on Tuesday, May 25, 2021 at 12:00 p.m. EDT 4D pharma plc ((AIM: DDDD, NASDAQ:LBPS), a pharmaceutical company lead
- 5y agoLBPS4D pharma to Present Additional Data from Phase II Study of Blautix for the Treatment of Irritable Bowel Syndrome at Digestive Disease Week (DDW) 2021Business WireCompany will host conference call on Tuesday, May 25, 2021 at 12:00 p.m. EDT 4D pharma plc ((AIM: DDDD, NASDAQ:LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the mic
- 5y agoLBPS4D pharma Collaborates With Parkinson's UK to Establish Patient Advisory BoardBusiness Wire4D pharma plc ((AIM: DDDD, NASDAQ:LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announces a collaboration with Parkinson's UK, a non-profit organ
- 5y agoLBPSFinal Results for the year ended 31 December 2020GlobeNewswireLeeds, UK, April 01, 2021 (GLOBE NEWSWIRE) -- 4D pharma plc (AIM: DDDD, NASDAQ: LBPS) (“4D”, the “Company” or, together with its subsidiaries, the “Group”), a pharmaceutical company leading the...
- 5y agoLBPSCompletion of Merger With Longevity Acquisition Corporation and Admission of American Depositary Shares to Trading on NASDAQBusiness WireLEEDS, United Kingdom--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD) ("4D" or the "Company"), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, is pleased to announce that its business combination with Longevity Acquisition Corporation, details of which were announced on 22 October 2020 (the "Merger"), has now b ...
- 5y agoLBPSLOAC4D pharma Announces Completion of Merger With Longevity Acquisition CorporationBusiness WireLEEDS, England--(BUSINESS WIRE)--4D pharma plc (Nasdaq: LBPS; AIM: DDDD) ("4D pharma" or the "Company"), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome - today announced completion of its merger (“the Merger”) with Longevity Acquisition Corporation ("Longevity")(Nasdaq: LOAC).